New Search

If you are not happy with the results below please do another search

Search
Generic filters

50 search results for:

4

Gilead Combo Therapy Hit with FDA Hold Over Serious Adverse Events

The U.S. Food and Drug Administration placed a partial clinical hold on studies conducted by Gilead Sciences assessing the combination of magrolimab plus azacitidine due to concerns of unexpected serious adverse events between study arms.

7

COVID is less severe with Omicron than Delta, U.S. study suggests

The Omicron variant appears to result in less severe COVID-19 than seen during previous periods of high coronavirus transmission including the Delta wave, with shorter hospital stays, less need for intensive care and fewer deaths, according to a new U.S. study.

9

Pandemic Health Systems Reimagined in Supermind Report

The MIT Center for Collective Intelligence and MilliporeSigma brought together the thought-power of gurus in science, healthcare, public policy and other sectors to answer the question: how do we apply what we have learned from the COVID-19 pandemic for the future?  

10

AstraZeneca’s Hematology Cornerstone is “Completely Replacing” Previous Standards

When AstraZeneca presented positive updated results from the Phase III ASCEND study of CALQUENCE (acalabrutinib), it marked an important milestone for the company as the jewel in the crown of what management hopes will become a significant hematology portfolio. That study was significant for patients, too, because it represented a landmark 36 months of follow-up in chronic lymphocytic leukemia (CLL), which is considered an incurable disease.